Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Early-stage triple-negative breast cancers, which lack expression of three proteins (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), have long been defined by what they are not. Now they have found a new identity and treatment approach: they are breast cancers that benefit from immune checkpoint inhibitor…

​   The New England Journal of Medicine: Search Results in Hematology/Oncology